Open AccessExamining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
Author(s) -
Abdulmohsen M. Alruwetei,
Katerina Bendak,
Babasaheb D. Yadav,
Hernán Carol,
Kathryn Evans,
Chelsea Mayoh,
Rosemary Sutton,
Glenn M. Marshall,
Richard B. Lock
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0933-4
Subject(s) - medicine , chemotherapy , bone marrow , vincristine , chemotherapy regimen , acute lymphocytic leukemia , oncology , asparaginase , regimen , induction chemotherapy , dexamethasone , leukemia , immunology , pathology , cyclophosphamide , lymphoblastic leukemia
While current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50-60%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission.